ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 79 filers reported holding ORIC PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $161,958 | -32.7% | 26,770 | -13.7% | 0.00% | – |
| Q2 2023 | $240,747 | +3912.4% | 31,024 | +2574.5% | 0.00% | – |
| Q1 2023 | $6,000 | +149900.0% | 1,160 | +52.6% | 0.00% | – |
| Q4 2022 | $4 | -100.0% | 760 | -94.5% | 0.00% | – |
| Q3 2022 | $44,000 | +63.0% | 13,744 | +132.1% | 0.00% | – |
| Q2 2022 | $27,000 | -74.3% | 5,922 | -69.9% | 0.00% | – |
| Q1 2022 | $105,000 | -54.9% | 19,654 | +23.9% | 0.00% | – |
| Q4 2021 | $233,000 | -49.2% | 15,860 | -27.7% | 0.00% | – |
| Q3 2021 | $459,000 | +57.7% | 21,940 | +33.5% | 0.00% | – |
| Q2 2021 | $291,000 | +1.7% | 16,435 | +40.8% | 0.00% | – |
| Q1 2021 | $286,000 | -15.1% | 11,674 | +17.3% | 0.00% | – |
| Q4 2020 | $337,000 | +349.3% | 9,951 | +206.6% | 0.00% | – |
| Q3 2020 | $75,000 | -64.3% | 3,246 | -47.8% | 0.00% | – |
| Q2 2020 | $210,000 | – | 6,217 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 4,768,181 | $161,403,000 | 14.64% |
| Invus Financial Advisors, LLC | 1,007,575 | $34,106,000 | 14.26% |
| Euclidean Capital LLC | 1,400,435 | $47,405,000 | 10.04% |
| Memorial Sloan Kettering Cancer Center | 602,272 | $20,387,000 | 8.63% |
| EcoR1 Capital, LLC | 3,092,218 | $104,672,000 | 5.63% |
| Ally Bridge Group (NY) LLC | 413,061 | $13,982,000 | 2.40% |
| Asymmetry Capital Management, L.P. | 67,210 | $2,275,000 | 1.04% |
| Orbimed Advisors | 2,921,967 | $98,909,000 | 0.86% |
| Casdin Capital, LLC | 601,515 | $20,361,000 | 0.60% |
| EMERALD ADVISERS, LLC | 522,302 | $17,680,000 | 0.59% |